Longitudinal evaluation of compressor/nebulizer performance
Inhaled medications are the mainstay of treatment for maintenance of lung health in patients with cystic fibrosis (CF). Compressor/nebulizer units are used an average of 100-120 min/d by patients with CF. Each compressor/nebulizer has unique flow/pressure characteristics that affect particle size di...
Gespeichert in:
| Veröffentlicht in: | Respiratory care 2014-07, Vol.59 (7), p.1053-1061 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1061 |
|---|---|
| container_issue | 7 |
| container_start_page | 1053 |
| container_title | Respiratory care |
| container_volume | 59 |
| creator | Awad, Samah Williams, David K Berlinski, Ariel |
| description | Inhaled medications are the mainstay of treatment for maintenance of lung health in patients with cystic fibrosis (CF). Compressor/nebulizer units are used an average of 100-120 min/d by patients with CF. Each compressor/nebulizer has unique flow/pressure characteristics that affect particle size distribution and drug output rate. Few data are available regarding longitudinal performance of compressor/nebulizers. We hypothesized that their use over a 24-wk period under conditions similar to those of patients with CF would affect their performance.
Four new units of compressor/reusable nebulizers from 3 brands (Pari Vios/Pari LC Plus, Pulmo-Aide 5650D/Viox, and Inspiration Elite/SideStream Plus) commonly used by patients with CF were tested. Compressor/nebulizers were operated for 1 h twice daily 5 d/wk for 24 wk. Compressor flow/pressure characteristics were measured every 6 wk. Maximal flow was recorded without and with the nebulizer (MF and MF/NEB, respectively). Pressure was recorded at zero flow (MP) and at MF/NEB (P/NEB). Particle size distribution, inhaled mass (IM), and IM in respirable range were evaluated at baseline and every 12 wk.
Vios had statistically significant declines in MP and P/NEB at each measurement compared with baseline (45.8 and 32.6 psi for MP and 16.7 and 14.3 psi for P/NEB at wk 0 and 24, respectively, P < .05), but other compressors did not. MF and MF/NEB were stable over time but significantly varied among brands. Vios had the greatest slope of flow/pressure relationship (Vios > Pulmo-Aide > Inspiration Elite). Two Vios units stopped working at wk 11 and 24, respectively. All compressors maintained baseline IM, IM in respirable range, and aerosol characteristics.
Long-term use of compressor/nebulizers in a regimen similar to that of patients with CF affected their performance. Pari Vios was the most affected brand, with declines in MP and P/NEB and 2 units that stopped working. Measurement of MF and MF/NEB could help identify compressors that are likely to fail. |
| doi_str_mv | 10.4187/respcare.02776 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1541378911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A377778200</galeid><sourcerecordid>A377778200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-4761f67d50560123b29727e522755e9a496b7a3a025c00b17f53da191f52df4b3</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhhdRbK1ePUpAEC9p9zPb4KkUv6DgRc_LZjPbRjbZuJsI-utNbRWdyzDwzMvMg9A5wVNO5nIWILZGB5hiKmV2gMYk5yxlmeCHaIwxxSlhlI_QSYyvw5hxkR-jEeWE55nEY3Sz8s266vqyarRL4F27XneVbxJvE-PrdsiPPswaKHpXfUJIWgjWh1o3Bk7RkdUuwtm-T9DL3e3z8iFdPd0_Lher1LCcdymXGbGZLAUWGSaUFTSXVIKgVAoBuR4uKaRmGlNhMC6ItIKVmuTEClpaXrAJut7ltsG_9RA7VVfRgHO6Ad9HRQQnTM5zQgb0coeutQNVNdZ3QZstrhZMDjWnGA_U1R9qA9p1m-hdv308_genO9AEH2MAq9pQ1Tp8KILV1r_68a--_Q8LF_tT-6KG8hf_Ec6-ABMUgBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1541378911</pqid></control><display><type>article</type><title>Longitudinal evaluation of compressor/nebulizer performance</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Awad, Samah ; Williams, David K ; Berlinski, Ariel</creator><creatorcontrib>Awad, Samah ; Williams, David K ; Berlinski, Ariel</creatorcontrib><description>Inhaled medications are the mainstay of treatment for maintenance of lung health in patients with cystic fibrosis (CF). Compressor/nebulizer units are used an average of 100-120 min/d by patients with CF. Each compressor/nebulizer has unique flow/pressure characteristics that affect particle size distribution and drug output rate. Few data are available regarding longitudinal performance of compressor/nebulizers. We hypothesized that their use over a 24-wk period under conditions similar to those of patients with CF would affect their performance.
Four new units of compressor/reusable nebulizers from 3 brands (Pari Vios/Pari LC Plus, Pulmo-Aide 5650D/Viox, and Inspiration Elite/SideStream Plus) commonly used by patients with CF were tested. Compressor/nebulizers were operated for 1 h twice daily 5 d/wk for 24 wk. Compressor flow/pressure characteristics were measured every 6 wk. Maximal flow was recorded without and with the nebulizer (MF and MF/NEB, respectively). Pressure was recorded at zero flow (MP) and at MF/NEB (P/NEB). Particle size distribution, inhaled mass (IM), and IM in respirable range were evaluated at baseline and every 12 wk.
Vios had statistically significant declines in MP and P/NEB at each measurement compared with baseline (45.8 and 32.6 psi for MP and 16.7 and 14.3 psi for P/NEB at wk 0 and 24, respectively, P < .05), but other compressors did not. MF and MF/NEB were stable over time but significantly varied among brands. Vios had the greatest slope of flow/pressure relationship (Vios > Pulmo-Aide > Inspiration Elite). Two Vios units stopped working at wk 11 and 24, respectively. All compressors maintained baseline IM, IM in respirable range, and aerosol characteristics.
Long-term use of compressor/nebulizers in a regimen similar to that of patients with CF affected their performance. Pari Vios was the most affected brand, with declines in MP and P/NEB and 2 units that stopped working. Measurement of MF and MF/NEB could help identify compressors that are likely to fail.</description><identifier>ISSN: 0020-1324</identifier><identifier>EISSN: 1943-3654</identifier><identifier>DOI: 10.4187/respcare.02776</identifier><identifier>PMID: 24149670</identifier><language>eng</language><publisher>United States: Daedalus Enterprises, Inc</publisher><subject>Administration, Inhalation ; Aerosols - administration & dosage ; Albuterol - administration & dosage ; Analysis ; Bronchodilator Agents - administration & dosage ; Care and treatment ; Cystic fibrosis ; Cystic Fibrosis - drug therapy ; Equipment Design ; Equipment Failure Analysis ; Health aspects ; Humans ; Mechanical properties ; Models, Biological ; Nebulizers and Vaporizers ; Particle Size ; Patient outcomes ; Respiratory agents ; Time Factors</subject><ispartof>Respiratory care, 2014-07, Vol.59 (7), p.1053-1061</ispartof><rights>Copyright © 2014 by Daedalus Enterprises.</rights><rights>COPYRIGHT 2014 Daedalus Enterprises, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-4761f67d50560123b29727e522755e9a496b7a3a025c00b17f53da191f52df4b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24149670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Awad, Samah</creatorcontrib><creatorcontrib>Williams, David K</creatorcontrib><creatorcontrib>Berlinski, Ariel</creatorcontrib><title>Longitudinal evaluation of compressor/nebulizer performance</title><title>Respiratory care</title><addtitle>Respir Care</addtitle><description>Inhaled medications are the mainstay of treatment for maintenance of lung health in patients with cystic fibrosis (CF). Compressor/nebulizer units are used an average of 100-120 min/d by patients with CF. Each compressor/nebulizer has unique flow/pressure characteristics that affect particle size distribution and drug output rate. Few data are available regarding longitudinal performance of compressor/nebulizers. We hypothesized that their use over a 24-wk period under conditions similar to those of patients with CF would affect their performance.
Four new units of compressor/reusable nebulizers from 3 brands (Pari Vios/Pari LC Plus, Pulmo-Aide 5650D/Viox, and Inspiration Elite/SideStream Plus) commonly used by patients with CF were tested. Compressor/nebulizers were operated for 1 h twice daily 5 d/wk for 24 wk. Compressor flow/pressure characteristics were measured every 6 wk. Maximal flow was recorded without and with the nebulizer (MF and MF/NEB, respectively). Pressure was recorded at zero flow (MP) and at MF/NEB (P/NEB). Particle size distribution, inhaled mass (IM), and IM in respirable range were evaluated at baseline and every 12 wk.
Vios had statistically significant declines in MP and P/NEB at each measurement compared with baseline (45.8 and 32.6 psi for MP and 16.7 and 14.3 psi for P/NEB at wk 0 and 24, respectively, P < .05), but other compressors did not. MF and MF/NEB were stable over time but significantly varied among brands. Vios had the greatest slope of flow/pressure relationship (Vios > Pulmo-Aide > Inspiration Elite). Two Vios units stopped working at wk 11 and 24, respectively. All compressors maintained baseline IM, IM in respirable range, and aerosol characteristics.
Long-term use of compressor/nebulizers in a regimen similar to that of patients with CF affected their performance. Pari Vios was the most affected brand, with declines in MP and P/NEB and 2 units that stopped working. Measurement of MF and MF/NEB could help identify compressors that are likely to fail.</description><subject>Administration, Inhalation</subject><subject>Aerosols - administration & dosage</subject><subject>Albuterol - administration & dosage</subject><subject>Analysis</subject><subject>Bronchodilator Agents - administration & dosage</subject><subject>Care and treatment</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Equipment Design</subject><subject>Equipment Failure Analysis</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Mechanical properties</subject><subject>Models, Biological</subject><subject>Nebulizers and Vaporizers</subject><subject>Particle Size</subject><subject>Patient outcomes</subject><subject>Respiratory agents</subject><subject>Time Factors</subject><issn>0020-1324</issn><issn>1943-3654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1Lw0AQhhdRbK1ePUpAEC9p9zPb4KkUv6DgRc_LZjPbRjbZuJsI-utNbRWdyzDwzMvMg9A5wVNO5nIWILZGB5hiKmV2gMYk5yxlmeCHaIwxxSlhlI_QSYyvw5hxkR-jEeWE55nEY3Sz8s266vqyarRL4F27XneVbxJvE-PrdsiPPswaKHpXfUJIWgjWh1o3Bk7RkdUuwtm-T9DL3e3z8iFdPd0_Lher1LCcdymXGbGZLAUWGSaUFTSXVIKgVAoBuR4uKaRmGlNhMC6ItIKVmuTEClpaXrAJut7ltsG_9RA7VVfRgHO6Ad9HRQQnTM5zQgb0coeutQNVNdZ3QZstrhZMDjWnGA_U1R9qA9p1m-hdv308_genO9AEH2MAq9pQ1Tp8KILV1r_68a--_Q8LF_tT-6KG8hf_Ec6-ABMUgBQ</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Awad, Samah</creator><creator>Williams, David K</creator><creator>Berlinski, Ariel</creator><general>Daedalus Enterprises, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Longitudinal evaluation of compressor/nebulizer performance</title><author>Awad, Samah ; Williams, David K ; Berlinski, Ariel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-4761f67d50560123b29727e522755e9a496b7a3a025c00b17f53da191f52df4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Inhalation</topic><topic>Aerosols - administration & dosage</topic><topic>Albuterol - administration & dosage</topic><topic>Analysis</topic><topic>Bronchodilator Agents - administration & dosage</topic><topic>Care and treatment</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Equipment Design</topic><topic>Equipment Failure Analysis</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Mechanical properties</topic><topic>Models, Biological</topic><topic>Nebulizers and Vaporizers</topic><topic>Particle Size</topic><topic>Patient outcomes</topic><topic>Respiratory agents</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Awad, Samah</creatorcontrib><creatorcontrib>Williams, David K</creatorcontrib><creatorcontrib>Berlinski, Ariel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Awad, Samah</au><au>Williams, David K</au><au>Berlinski, Ariel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal evaluation of compressor/nebulizer performance</atitle><jtitle>Respiratory care</jtitle><addtitle>Respir Care</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>59</volume><issue>7</issue><spage>1053</spage><epage>1061</epage><pages>1053-1061</pages><issn>0020-1324</issn><eissn>1943-3654</eissn><abstract>Inhaled medications are the mainstay of treatment for maintenance of lung health in patients with cystic fibrosis (CF). Compressor/nebulizer units are used an average of 100-120 min/d by patients with CF. Each compressor/nebulizer has unique flow/pressure characteristics that affect particle size distribution and drug output rate. Few data are available regarding longitudinal performance of compressor/nebulizers. We hypothesized that their use over a 24-wk period under conditions similar to those of patients with CF would affect their performance.
Four new units of compressor/reusable nebulizers from 3 brands (Pari Vios/Pari LC Plus, Pulmo-Aide 5650D/Viox, and Inspiration Elite/SideStream Plus) commonly used by patients with CF were tested. Compressor/nebulizers were operated for 1 h twice daily 5 d/wk for 24 wk. Compressor flow/pressure characteristics were measured every 6 wk. Maximal flow was recorded without and with the nebulizer (MF and MF/NEB, respectively). Pressure was recorded at zero flow (MP) and at MF/NEB (P/NEB). Particle size distribution, inhaled mass (IM), and IM in respirable range were evaluated at baseline and every 12 wk.
Vios had statistically significant declines in MP and P/NEB at each measurement compared with baseline (45.8 and 32.6 psi for MP and 16.7 and 14.3 psi for P/NEB at wk 0 and 24, respectively, P < .05), but other compressors did not. MF and MF/NEB were stable over time but significantly varied among brands. Vios had the greatest slope of flow/pressure relationship (Vios > Pulmo-Aide > Inspiration Elite). Two Vios units stopped working at wk 11 and 24, respectively. All compressors maintained baseline IM, IM in respirable range, and aerosol characteristics.
Long-term use of compressor/nebulizers in a regimen similar to that of patients with CF affected their performance. Pari Vios was the most affected brand, with declines in MP and P/NEB and 2 units that stopped working. Measurement of MF and MF/NEB could help identify compressors that are likely to fail.</abstract><cop>United States</cop><pub>Daedalus Enterprises, Inc</pub><pmid>24149670</pmid><doi>10.4187/respcare.02776</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-1324 |
| ispartof | Respiratory care, 2014-07, Vol.59 (7), p.1053-1061 |
| issn | 0020-1324 1943-3654 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1541378911 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Administration, Inhalation Aerosols - administration & dosage Albuterol - administration & dosage Analysis Bronchodilator Agents - administration & dosage Care and treatment Cystic fibrosis Cystic Fibrosis - drug therapy Equipment Design Equipment Failure Analysis Health aspects Humans Mechanical properties Models, Biological Nebulizers and Vaporizers Particle Size Patient outcomes Respiratory agents Time Factors |
| title | Longitudinal evaluation of compressor/nebulizer performance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A30%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20evaluation%20of%20compressor/nebulizer%20performance&rft.jtitle=Respiratory%20care&rft.au=Awad,%20Samah&rft.date=2014-07-01&rft.volume=59&rft.issue=7&rft.spage=1053&rft.epage=1061&rft.pages=1053-1061&rft.issn=0020-1324&rft.eissn=1943-3654&rft_id=info:doi/10.4187/respcare.02776&rft_dat=%3Cgale_proqu%3EA377778200%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1541378911&rft_id=info:pmid/24149670&rft_galeid=A377778200&rfr_iscdi=true |